FDA Panel To Decide Whether New Breast, Prostate Cancer Drugs Are Worth The Risks

Summaries of health policy coverage from major news organizations Wednesday, Apr 29 2026 9:06 AM Full Issue FDA staff have expressed concerns about the use of camizestrant to treat metastatic breast cancer and capivasertib for patients with metastatic hormone-sensitive prostate cancer. The Oncologic Drugs Advisory Committee will vote on these two drug applications Thursday. MedPage…

Read Full News

3 Drugs On Horizon Could Help Lower Lp(a), A Genetic Form Of Cholesterol That Raises Heart Attack Risk

Summaries of health policy coverage from major news organizations Tuesday, Apr 28 2026 Full Issue At least three pharma firms — Novartis, Amgen, and Eli Lilly — say they’re closer to unraveling the mystery of lipoprotein(a), which is a more dangerous cousin to LDL cholesterol. Diet and exercise don’t influence lp(a) levels, CNBC reported, and…

Read Full News